In that line, our group made an association between the levels of WT1-specific CD8 + T cells targeting different WT1-epitopes and the clinical response of AML patients following a WT1-based dendritic cell vaccine [11], while Hoffman et al. discovered that patients responding to donor lymphocyte infusion (DLI) targeted more leukemia associated epitopes than those who did not respond [69]. The gene discussed is WT1; the disease is leukemia.